Trial Profile
A PHASE III, RANDOMIZED, MULTICENTERIC, CONTROLLED STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF BBIL's TYPHOID Vi CAPSULAR POLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCE VACCINE IN HEALTHY SUBJECTS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
- Indications Typhoid
- Focus Pharmacodynamics; Registrational
- Sponsors Bharat Biotech
- 05 Oct 2021 Results from CTRI2014-01-004341 and CTRI2011-08-001957, for follow on monitoring of serum IgG Vi antibody titers at 3, 5, and 7 years after initial vaccination of infants/toddlers, including those who did, or did not, receive a booster vaccination 720 days post primary immunization, published in the Vaccine
- 17 Jan 2018 Results published in the Clinical Infectious Diseases
- 26 Aug 2013 Results have been reported in a Bharat Biotech media release.